Welcome to our dedicated page for Bolt Biotherapeutics news (Ticker: BOLT), a resource for investors and traders seeking the latest updates and insights on Bolt Biotherapeutics stock.
Bolt Biotherapeutics develops cancer immunotherapies using its Boltbody™ Immune-Stimulating Antibody Conjugate platform and myeloid-biology programs. Company updates focus on BDC-4182, a next-generation claudin 18.2 ISAC clinical candidate for gastric and gastroesophageal cancers, along with BDC-3042, a Dectin-2 agonist antibody, and preclinical ISAC programs targeting CEA and PD-L1.
Recurring news also includes clinical and preclinical data presentations, quarterly financial results, cash runway commentary, collaboration activity with Genmab and Toray, partnering process disclosures for pipeline assets, conference participation, and cost-control actions tied to the company’s oncology research and development strategy.
Bolt Biotherapeutics reported a strong cash position of $302.9 million as of March 31, 2021, which is anticipated to support operations into 2023. The company successfully raised $264.5 million from its upsized IPO in February 2021. Bolt is progressing on its lead program, BDC-1001, with a Phase 1/2 trial expected to provide updates in the second half of 2021. In Q1 2021, R&D expenses rose to $14.1 million, while the loss from operations increased to $24.5 million. The company's strategic initiatives aim to enhance shareholder value through ongoing clinical trials and pipeline advancements.
Bolt Biotherapeutics (Nasdaq: BOLT) announced the ongoing Phase 1/2 study of its lead clinical candidate, BDC-1001, at the AACR Annual Meeting 2021. This first-in-class HER2-targeting immune-stimulating antibody conjugate is designed to convert cold tumors into hot ones, enhancing anti-tumor immune response. The study involves evaluating safety and efficacy in up to 390 patients with HER2-expressing tumors. Initial results showed promising signs of clinical activity and acceptable safety with no dose-limiting toxicities reported.
Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biotechnology company, is set to present at the 20th Annual Needham Virtual Healthcare Conference on April 15, 2021, at 10:15 AM ET. CEO Randall C. Schatzman, Ph.D., will provide an overview of the company. Bolt is pioneering immuno-oncology agents, specifically Boltbody™ Immune-stimulating Antibody Conjugates (ISACs), which aim to convert ‘cold’ tumors to ‘hot’ tumors. Their lead candidate, BDC-1001, targets HER2-expressing solid tumors and is currently in phase 1/2 clinical testing.
Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) reported strong fundraising outcomes, raising $358 million through an upsized IPO and Series C financing. The company announced positive preliminary results from its Phase 1/2 trial of BDC-1001, targeting HER2-expressing solid tumors, showing clinical activity in 20 treated patients. R&D expenses increased to $40.4 million in 2020 from $26 million in 2019. Despite a reported loss from operations of $49.2 million for the year, the company maintains a strong cash position to fund operations into 2023.
Bolt Biotherapeutics, Inc. (Nasdaq: BOLT) has successfully closed its initial public offering, selling 13,225,000 shares at $20.00 each. This includes the full exercise of the underwriters' option for an additional 1,725,000 shares. The company specializes in developing immune-oncology therapies, particularly its lead candidate BDC-1001, aimed at HER2-expressing solid tumors. The offering was managed by Morgan Stanley, SVB Leerink, Stifel, and Guggenheim Securities.